Provexis shares are showing a gain following final results that guided that sales for the six months to 30 September 2026 should exceed £1.05m, at least 188% ahead of a year earlier, although the company still carries a material going concern uncertainty.

The renewed interest in Provexis (LSE:PXS) appears to stem from the sales guidance in its final results for the year to 31 March 2026, published on 30 September 2026. In that announcement, the company said it expects to report sales for the six months to 30 September 2026 in excess of £1.05m, at least 188% ahead of the £364k recorded in the same period a year earlier. The company expects to publish formal half-year figures in due course, but no date has yet been given. There has been no announcement since 30 September, so the latest move in the shares has no confirmed news trigger.

On 15 October 2026, market data showed the shares at 1.10p, up 0.15p (+15.79%) from a previous close of 0.95p, on volume of 245,049. That headline price did not match the last listed trade, which was 52,000 shares at 0.95p, so the intraday figures should be treated with caution. The company's annual general meeting is set for 20 November 2026. Provexis is one of the stocks drawing heavy discussion among UK investors today.

The Sales Guidance in Context

The comparison with last year is flattered by a weak prior period. In the half-year to 30 September 2025, revenue was £364,369, down from £785,348 a year before. Provexis explained at the time that a production run completed in October 2025 had arrived two months later than envisaged, which reduced August and September 2025 sales. That episode illustrates how heavily reported revenue in any six-month window can depend on when production runs are completed and shipped.

The full year to 31 March 2026 showed how sales recovered after that delay. Revenue was £1,264,531 (2025: £1,292,244), and the second half was a record, at over £900k. Sales split between:

  • Fruitflow II SD (business-to-business): £1,148,623
  • Fruitflow+ Omega-3 (consumer): £115,908

In their joint statement, Chairman Dawson Buck and Chief Executive Ian Ford said the company had made good progress over the year and that "the Company expects in due course to report total sales for the six months ended 30 September 2026 in excess of £1.05m". They also pointed to "a number of additional production runs of Fruitflow II SD in the next twelve months", which they said would help "to support the planned launch of a number of Fruitflow based products in the Chinese market".

The Business at a Glance

Provexis owns Fruitflow®, a tomato-based ingredient for heart and circulatory health. It took over the Fruitflow business from dsm-firmenich (DSM) under agreements effective 1 January 2023, and it now sells both a business-to-business ingredient and a consumer product.

Its supply and distribution partner in China is BYHEALTH, under an agreement dating from November 2021. BYHEALTH's submission to China's SAMR for a new health function claim is ongoing, with no outcome yet. Allenby Capital Limited is the company's adviser and broker contact. Provexis is incorporated in England and Wales, and its AIM Rule 26 page states that the company is not listed on any other exchanges or trading platforms.

DSM remains a shareholder through DSM Venturing BV, although its stake has fallen. It moved from 10.94% to 9.958% in April 2026, and then to 8.802% (206,493,074 voting rights) after crossing a threshold on 18 May 2026.

Financial Position and the DSM Royalty

The final results showed a business still running at a loss:

  • Loss from operations: £511,558 (2025: £451,971), including £308,587 of share-based payment charges
  • Underlying operating loss: £192,263 (2025: £278,152)
  • Loss after tax: £502,760 (2025: £452,720); loss per share 0.02p; no dividend
  • Cash: £893,141 (2025: £708,087)
  • Net assets: £572,288 (2025: £763,815)
  • Trade and other payables: £707,088 (2025: £239,621)

No borrowings were shown on the balance sheet. Earlier share issues raised £294,159 in April 2024 and £563,471 in December 2024. Weighted average shares were 2,345,891,239 in the year, and market data shows about 2.35b shares in issue and a market capitalisation of £25.80m.

One of the more important moving parts is the royalty arrangement with DSM. Royalty negotiations for the period to 31 December 2026 have not yet been concluded, and Provexis (LSE:PXS) says it will seek to settle them in shares. The royalties cease to be payable from 1 January 2027, which would remove that obligation for future periods. Until that negotiation is complete, the cost and the number of shares involved remain unknown.

Risks to Weigh

The results carried a significant warning. The directors and the auditor flag a material uncertainty related to going concern, linked to three inherently uncertain forecasting issues: the size of production runs, revenue outcomes and the unconcluded DSM royalty negotiations.

Other risks include:

  • Funding and dilution: the company may need share or loan finance, larger production runs need significant cash, and the DSM royalties are expected to be settled in shares.
  • Execution: sales depend on the timing of production runs, and the 2025 run slipped by two months.
  • Regulatory: the China SAMR health-claim submission has no outcome yet.
  • Trading: the price data on 15 October showed a gap between the headline price and the last listed trade, and the bid was 0.80p against an ask of 1.00p.

The rise in trade and other payables, from £239,621 to £707,088, is also worth noting alongside the cash balance of £893,141.

What to Watch Next

  • The formal half-year results for the six months to 30 September 2026, for which no date has been set
  • The AGM at 12:30pm on 20 November 2026, at Allenby Capital Limited, 5th Floor, 5 St Helen's Place, London EC3A 6AB
  • The outcome of DSM royalty negotiations and any shares issued to settle them
  • Further Fruitflow II SD production runs over the next twelve months
  • Any decision on BYHEALTH's SAMR health function claim in China

Provexis has given the market a clear number to anchor on: sales above £1.05m for the six months to 30 September 2026, well ahead of a delay-affected prior period. That guidance, together with a record second half and a higher cash balance, offers one explanation for renewed attention on the shares, which have traded between 0.55p and 1.55p over the past 52 weeks. Against that, the company remains loss-making, its going concern statement carries a material uncertainty, and the DSM royalty settlement could add new shares. The formal half-year figures and the 20 November AGM should give a fuller picture.